Skip to main content

Table 1 Patient baseline characteristics (n = 780)

From: Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants

  Group A
Bridging
n = 111
Group B
VKA
n = 318
Group C
DOAC
n = 351a
p-value
A-B
p-value
A-C
p-value
B-C
Age (years) 59.1 ± 9.8 59.6 ± 10.2 59.5 ± 10.0 0.706 0.809 0.841
Female gender 32 (29) 98 (30) 115 (32.8) 0.721 0.484 0.618
BMI (kg/m2) 28.0 ± 4.07 27.9 ± 4.6 28 ± 10 0.629 0.919 0.822
Ejection fraction (%) 63 ± 11.4 62 ± 8 63 ± 5 0.797 0.276 0.077
Atrial fibrillation     0.316 0.092 < 0.001
 Paroxysmal AF 57 (51.4) 137 (43.1) 221 (63.0)    
 Persistent AF 43 (38.7) 142 (44.7) 102 (29.1)    
 Atypical AF 28 (8.0) 39 (12.3) 28 (8.0)    
LA Diameter (mm) 44.2 ± 5.5 43.3 ± 4.7 41.5 ± 4.3 0.093 < 0.001 < 0.001
Comorbidity
 Hypertension 90 (80.1) 237 (74.5) 228 (65) 0.195 0.001 0.009
 CAD 23 (20.7) 53 (16.7) 41 (11.7) 0.386 0.026 0.075
 Diabetes 7 (6.3) 28 (8.8) 24 (6.8) 0.546 1.0 0.387
 Stroke/TIA 7 (6.3) 19 (6.0) 54 (5.7) 1.0 0.813 0.867
  1. Legend: aDabigatran (n = 170), Rivaroxaban (n = 112), Apixaban (n = 69); AF atrial fibrillation, BMI body-mass-index, EF ejection fraction, CAD coronary artery disease, Bridging interrupted vitamin-K-antagonist bridged with heparin, DOAC uninterrupted non-vitamin-K anticoagulants, TIA transient ischemic attack, VKA uninterrupted vitamin-K-antagonist